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Introduction
Infants and children with congenital cyanotic defects
have their hearts chronically perfused with hypoxemic
blood. These children show myocardial damage after
surgical correction of their heart defects [5, 6, 12, 17,
21, 22]. Institution of cardiopulmonary bypass in
these infants exposes the cyanotic heart to sudden
reoxygenation. Amongst all conditions that cause
myocardial injury, periods of prolonged hypoxemia
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j Abstract Children with congenital cyanotic heart defects have worse
outcomes after surgical repair of their heart defects compared with
noncyanotic ones. Institution of extracorporeal circulation in these
children exposes the cyanotic heart to reoxygenation injury. Mitogen-
activated protein kinase (MAPK) signaling cascades are major regulators
of cardiomyocyte function in acute hypoxia and reoxygenation. However,
their roles in chronic hypoxia are incompletely understood. We
determined myocardial activation of the three major MAPKs, c-Jun
NH2-terminal kinase (JNK), extracellular signal-regulated kinase-1/2
(ERK1/2), and p38-MAPK in adult rats exposed to hypoxia (FIO2 = 0.10)
for varying periods of time. Myocardial function was analyzed in isolated
perfused hearts. Acute hypoxia stimulated JNK and p38-MAPK activa-
tion. Chronic hypoxia (2 weeks) was associated with increased p38-
MAPK (but not JNK) activation, increased apoptosis, and impaired
posthypoxic recovery of LV function. Brief normoxic episodes (1 h/day)
during chronic hypoxia abolished p38-MAPK activation, stimulated
MEK-ERK1/2 activation modestly, and restored posthypoxic LV function.
In vivo p38-MAPK inhibition by SB203580 or SB202190 in chronically
hypoxic rats restored posthypoxic LV function. These results indicate
that sustained hypoxemia maintains p38-MAPK in a chronically activated
state that predisposes to myocardial impairment upon reoxygenation.
Brief normoxic episodes during chronic hypoxia prevent p38-MAPK
activation and restore posthypoxic recovery of myocardial function.
j Key words Mitogen-activated protein kinases – MAPK – p38 –
hypoxia – reoxygenation
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followed by abrupt reoxygenation cause some of the
most damaging and irreversible consequences.
Experimental evidence suggests that immature hearts
are tolerant to ischemia and reperfusion, but sus-
ceptible to reoxygenation injury during cardiopul-
monary bypass without aortic clamping [11]. Clinical
evidence in cyanotic infants and children undergoing
surgical repair of congenital heart defects suggests
that chronic hypoxemia followed by sudden reoxy-
genation on cardiopulmonary bypass causes free
radical production and impaired postbypass con-
tractility [5, 6, 12]. Ensuing low-output syndrome is
the leading cause of prolonged and complicated
courses after successful heart surgery in cyanotic in-
fants and children [12, 17, 21, 22].
Stress and mitogen-activated protein kinases
(MAPKs) are a family of serine/threonine protein
kinases that are activated in response to various
extracellular stimuli such as chemical stress, physical
stress, radiation, and G-protein-coupled receptor
activation. Three major MAPK signaling cascades
include stress-activated protein kinases (SAPKs)/c-
Jun N-terminal kinases (JNKs), p38-MAPK (p38a,
p38b, p38c, and p38d isoforms), and extracellular
signal-regulated kinases (ERKs). Acute myocardial
hypoxia and reoxygenation stimulates MAPK activa-
tion [19]. However, the roles of MAPKs in chronic
hypoxia are still incompletely understood. A recent
study showed increased JNK and p38-MAPK activa-
tion in cardiac tissues from hypoxic infant rabbits and
humans [23]. In the rabbit model, pups were housed
in hypoxic chambers but were allowed to return to
their mothers and, hence, to breathe room air for a
30-min feeding period daily [23].
Traditionally, hypoxic or hypobaric chambers that
were used in previous studies required exposure to
room air for a 15–30-min feeding and cleaning period
daily [2, 13, 23]. To avoid this confounding factor, we
have designed new normobaric hypoxic chambers that
allow for daily animal care, drug injection, sacrifice,
and organ recovery in the absence of any exposure to
room air [3, 20]. Therefore, the myocardium is chron-
ically perfused with hypoxemic blood. This nonsurgical
model mimics physiological (high-altitude) and path-
ological (congenital heart defects, obstructive lung
disease, anemia, microvascular disease) conditions of
impaired tissue oxygenation. Unlike previous studies,
we used a hypoxic perfusate for initial equilibration of
the isolated hypoxic heart to avoid premature reoxy-
genation. Thus, our model permits to study the re-
sponse of chronically hypoxemic hearts to the first
exposure to high O2 tensions. We used this model to
assess myocardial MAPK activation in chronic hypoxia
and subsequent reoxygenation. Since previous studies
using conventional hypoxic chambers required inter-
mittent exposure to room air, we also studied the effect
of repeated brief normoxic episodes on MAPK activa-
tion in chronically hypoxic hearts.
Methods
j Experimental groups
Animal experimentation conformed with the Guide for the Care
and Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 8523, revised 1996).
Animals were housed in normobaric hypoxic plexiglas chambers
that allow for daily maintenance in the absence of any exposure to
room air [3]. The oxygen tension inside the hypoxic chamber was
continuously monitored by an O2 electrode. We assessed MAPK
activation after exposure to a hypoxic environment (fraction of
inspired oxygen [FIO2] = 0.10) for varying periods of time (Fig. 1).
Sprague–Dawley male rats (5 weeks of age; purchased from IFFA-
Credo, L’Arbresle, France) were subdivided into five groups (n = 6/
group): (1) Normoxia (N; room air, [FIO2] = 0.21); (2) Acute Hy-
poxia (AH; 1 h); (3) Sub-Acute Hypoxia (SAH; 23 h); (4) Chronic
Hypoxia (CH; 2 weeks); (5) CH with intermittent normoxic Aera-
tion (CHA; FIO2 = 0.10 for 23 h/day and 0.21 for 1 h/day during
2 week). To assess the acute effect of a normoxic episode on MAPK
activation in SAH, CH, and CHA, additional rats (n = 4/group)
were exposed to room air for 1 h before the sacrifice.
j Isolation of cytosolic and nuclear fractions
For sacrifice, the rat was moved to a compensation hypoxic
chamber attached to the main chamber (same FIO2) and injected
with a lethal dose of sodium thiopental and 1500 U heparin IP, as
described [3]. The heart was explanted and rinsed in ice-cold PBS
(pH 7.4) inside the chamber. Separation of cytosolic and nuclear
proteins was performed according to a published protocol [8]. The
heart was freeze-clamped between steel tongs pre-cooled with li-
quid nitrogen. Frozen tissue was homogenized in lysis buffer
solution (Hepes 10 mM, KCl 10 mM, EDTA 0.1 mM, EGTA
0.1 mM, DTT 1 mM, Triton-X100 0.5%, PMSF 0.5 mM, sodium-
orthovanadate 1 mM, ß-glycerophosphate 10 mM, NaF 50 mM)
AH
SAH
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Fig. 1 Scheme of the study protocol. Experimental groups include normoxia
(N), acute hypoxia (AH), subacute hypoxia (SAH), chronic hypoxia (CH); and CH
with a 1-h normoxic aeration daily (CHA). Grey horizontal bars indicate hypoxia;
white spaces, normoxia (the time scale is not linear)
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containing Protease Inhibitor Cocktail (Roche). After incubation on
ice (10 min), nuclear and cytosolic proteins were separated by
centrifugation (1000 · g, 4C, 5 min). Supernatant containing
cytosolic proteins was transferred to a pre-cooled microcentrifuge
tube, frozen in liquid nitrogen, and stored at )80C. The pellet was
incubated (4C, 1 h) in lysis buffer solution (Hepes 20 mM, NaCl
400 mM, EDTA 1 mM, EGTA 1 mM, DTT 1 mM, PMSF 1 mM,
sodium-orthovanadate 1 mM, ß-glycerophosphate 10 mM, NaF
50 mM, protease inhibitors). After centrifugation (10,000 · g, 4C,
15 min), supernatant containing nuclear proteins was transferred
to a cold microcentrifuge tube, frozen in liquid nitrogen, and stored
at )80C. Total protein in each fraction was measured by a mod-
ified Lowry assay using bovine serum albumin (BSA) as a standard.
Purity of cytosolic and nuclear fractions was tested by Western
using anti-ß-actin and anti-histone deacetylase-1 (HDAC-1) anti-
bodies, respectively.
j Western blot analysis
SDS-PAGE Western blotting was performed as follows: Proteins
(80 lg) from cytosolic or nuclear fractions were heated at 95C for
5 min, followed by electrophoresis on a 12% denaturating gel, and
electroblotting onto PVDF membranes. Loading of equal amounts
of each MAPK protein for each tissue sample was verified by the
intensities of bands obtained with nonphospho-specific antibodies
for each MAPK. Membranes were incubated with 5% nonfat dry
milk in TBS-Tween buffer (1 h), followed by primary antibody
(4C, overnight), and HRP-conjugated secondary antibody (RT,
1 h). Phosphorylated MAPK protein levels were determined with
phospho-specific antibodies (Cell Signaling Technologies; CST)
that recognize phospho-JNK (Thr183/Tyr185), phospho-ERK1/2
(Thr202/Tyr204), or phospho-p38 MAPK (Thr180/Tyr182). Im-
munoblots were developed by using the LumiGlo reagent/peroxide
chemiluminescent system (CST). Band intensities were quantified
by using the NIH AutoExtractor-1.51 software. An extract from one
normoxic heart was loaded on all blots for quantitative compari-
sons between blots. Data were normalized to normoxic controls
and shown as fold-increases over normoxic levels.
j Immunoprecipitation and in vitro kinase assays
MAPK activities were determined in nuclear and cytosolic fractions
by immunoprecipitation, followed by in vitro kinase assays using
specific substrates for each MAPK (n = 6/group). For determination
of JNK activity, 100 lg of tissue extract was incubated (RT, 1 h) with
1 lg glutathione S-transferase (GST)–c-Jun coupled with glutathione
beads, as described [1]. After centrifugation (10,000 · g, 1 min), the
supernatant was removed and the beads were washed twice. Beads
were resuspended (30C, 30 min) in 20 ll kinase buffer solution
(Hepes 20 mM, pH 7.5, ß-glycerophosphate 20 mM, MgCl2 10 mM,
DTT 1 mM,) containing 1 ll [c-33P]ATP (3000 ci/mmol; Amer-
sham). Samples were heated at 95C for 5 min, followed by elec-
trophoresis on a 12% denaturating gel. Phosphorylated c-jun was
resolved by autoradiography. For determination of p38-MAPK and
ERK1/2 kinase activities, 200 lg tissue extract was incubated (4C,
overnight) with anti-phospho-p38-MAPK or anti-phospho-ERK1/2,
20 ll sepharose-A beads (Amersham), and 50 ll BSA. The pellet was
washed twice with lysis buffer and twice with kinase buffer solution
(Tris 25 mM, pH 7.5, ß-glycerophosphate 5 mM, DTT 2 mM, so-
dium-orthovanadate 0.1 mM, MgCl2 10 mM) and incubated (30C,
30 min) with 50 ll kinase buffer solution supplemented with
200 lM ATP and 2 lg ATF-2 or ELK-1 fusion proteins (CST) as p38-
MAPK and ERK1/2-specific substrates, respectively. Reaction was
terminated by adding 25 ll 3· SDS buffer (Tris–HCl 187.5 mM, pH
6.8, SDS 6%, glycerol 30%, DTT 150 mM, bromophenol blue 0.03%).
Samples were heated at 95C for 5 min, followed by electrophoresis
on a 12% denaturating gel, and electroblotting onto nitrocellulose
membrane. These were incubated (4C, overnight) with anti-phos-
pho-ATF-2 (Thr71) or anti-phospho-ELK-1 (Ser383) (CST), fol-
lowed by HRP-conjugated secondary antibody (RT, 1 h).
Immunoblots were developed with LumiGlo reagent/peroxide.
j Assessment of oxidative stress and apoptosis
To assess oxydative stress and myocardial response to hypoxia, we
measured plasma malondialdehyde (MDA; an index of lipid per-
oxidation) and nitrates–nitrites (NOx; an index that reflects NO
production), as described previously [20]. Apoptosis was deter-
mined on sections of N, AH, SAH, CH, and CHA hearts (n = 4–6/
group) that were immediately processed after the sacrifice. We used
terminal deoxynucleotidyl transferase-mediated dUTP-rhodamine
nick end labeling (TUNEL; ApopTag Red In Situ Apoptosis
detection kit; Intergen). Data are numbers of TUNEL-positive nu-
clei/microscopic field (mean values ± SEM) on five random fields
(area: 0.037 mm2 each) per heart section (magnification: 400·).
j Isolated heart perfusion and MAPK inhibitors
Rat hearts (n = 7–11/group) were recovered inside the hypoxic
chamber, perfused in a retrograde manner with a hypoxic solution,
and instrumented as described [3]. After initial equilibration
(30 min), hearts were reoxygenated (94% O2) for 30 min. Rats
exposed to CH received either no treatment, SB202190 or SB203580
(1 mg/kg body weight IP; Calbiochem). Both pyridinylimidazole
p38-MAPK inhibitors blocking the kinase catalytic site were given
1 h before sacrifice. Inhibitory effect on p38-MAPK activity was
tested by measuring phosphorylation of Hsp27, a target of p38-
MAPK, in heart extracts by Western using anti-phospho-Hsp27
[15] Ab (Santa Cruz Biotech.). Normoxic rats that received either
p38-MAPK inhibitor, as well as CH rats that received vehicle alone
were used as controls. CHA rats either received no treatment, two
doses of PD980592 (2.5 mg/kg body weight/dose IP), a potent and
selective inhibitor of MAPK/ERK kinase (MEK1, the upstream
activator kinase of ERK1/2) given 6 h and 30 min before sacrifice,
or vehicle alone (two doses).
j Statistical analysis
Statistical analysis of MAPK activation was performed by use of
ANOVA. If significant, the Mann–Whitney test was used as a sec-
ond step to identify significant differences between individual
groups. Analysis of functional recovery in isolated hearts was
performed by use of one-way ANOVA with Bonferroni’s post-hoc
test. Significance was set at P < 0.05.
Results
j Blood and morphologic data
Blood and morphologic data are shown in Table 1.
The O2 level in the hypoxic chamber never increased
by >1% during normal maintenance and by >2%
during sacrifice. Arterial pO2 was 34–38 mmHg in
both CH and CHA versus 60–70 mmHg in N.
Hematocrit, hemoglobin concentration, red blood cell
counts, plasma MDA, and NOx were increased in both
CH and CHA, with a higher increase in NOx in CHA
versus CH (P < 0.05). CHA and CH resulted in re-
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duced net weight gain and weight loss, respectively.
The heart weight/body weight ratio (an index of car-
diac hypertrophy) and the RV/LV+septum weight
ratio (an index of RV hypertrophy) were increased in
both CH and CHA.
j Phosphorylated (activated) MAPK protein levels
In normoxic hearts, phosphorylated JNK, ERK1/2, and
p38-MAPK proteins were present in both cytosolic and
nuclear fractions. In combined fractions, phospho-
JNK protein levels were increased (fold) by 2.4 in AH
(P < 0.01), 1.8 in SAH (NS), 1.5 in CH (NS), and 1.8 in
CHA (NS; Fig. 2A). Phospho-ERK1/2 protein levels in
combined fractions were minimally increased in AH
and SAH (NS), unchanged in CH, and increased by 1.6-
fold in CHA (P < 0.05). Phospho-ERK1/2 protein lev-
els in nuclear fractions were increased by 1.9-fold in
CHA (P < 0.05 and < 0.01 versus N and CH, respec-
tively; Fig. 2C). Phospho-p38-MAPK protein levels
were increased (fold) by 3.9 in AH (P < 0.01) and 2.4 in
CH (P < 0.05), but marginally decreased in CHA.
Phospho-p38-MAPK in nuclear fractions was in-
creased by 4.6-fold in CH (P < 0.01 versus CHA;
Fig. 2E). A single normoxic exposure for 1 h reduced
phospho-p38-MAPK in SAH and CH by ~60% and
~30%, respectively, while phospho-JNK and phospho-
ERK1/2 were essentially unaffected (data not shown).
j MAPK in vitro kinase activities
Changes in specific in vitro kinase activities paralleled
those in phospho-MAPK protein levels. JNK kinase
activity was increased (fold) by 2.8 in AH (P < 0.01),
2.0 in SAH (P < 0.05), 1.3 in CH (NS), and 2.2 in CHA
(P < 0.05; Fig. 2B). ERK1/2 activity was essentially
unchanged in AH, SAH and CH, but was increased by
1.6-fold in CHA (P < 0.05; Fig. 2D). p38-MAPK
activity in cytosolic fractions was increased in AH but
not under the other conditions. p38-MAPK activity in
nuclear fractions was increased (fold) by 4.9 in AH
(P < 0.01), 1.7 in SAH, and 2.3 in CH (P < 0.01),
whereas it was marginally decreased in CHA (Fig. 2F).
Thus, p38-MAPK activity in nuclear fractions was
reduced by a factor of 3.3 in CHA compared with CH
(P < 0.01).
j Apoptosis
Numbers of apoptotic cells were determined in both
normoxic and hypoxic hearts that were processed
immediately after the sacrifice (in the absence of
perfusion of the isolated heart). TUNEL-positive cell
counts were significantly increased in AH, SAH and
CH, unlike CHA (Fig. 3).
j In vivo p38-MAPK inhibition
Phosphorylation of Hsp27 was increased 3.6-fold in
CH, indicating increased p38-MAPK activation, but it
was suppressed by both SB203580 and SB202190,
indicating effective p38-MAPK inhibition (Fig. 4).
j Posthypoxic recovery of LV function
Recovery of LV function upon sudden reoxygen-
ation was analyzed in isolated perfused hearts.
Baseline measurements of LV developed pressure
(LVDP), heart rate (HR), the LVDP · HR product
(Fig. 5), and LV enddiastolic pressure (LVEDP;
Fig. 6) were not different between groups. Post-
hypoxic recovery of LVDP · HR was impaired in
CH but restored in CHA (Fig. 5A, E). Both
SB203580 and SB202190 restored LVDP · HR in CH
(Figures 5B,C). Neither p38-MAPK inhibitor affected
Table 1 Blood and morphological
data in normoxic (N), chronically
hypoxic (CH), and CH rats exposed to
1-h normoxic aeration daily (CHA)
Controls CH CHA
N 9 11 8
Initial body weight, g 249 ± 18 247 ± 7 252 ± 6
Hematocrit 0.44 ± 0.01 0.69 ± 0.01a 0.68 ± 0.01a
Hemoglobin, g/l 139 ± 4 220 ± 5a 215 ± 2a
Red blood cell count, RBC/ll/1000 7.00 ± 0.15 10.26 ± 0.16a 9.77 ± 0.19a
Final body weight, g 351 ± 13 194 ± 9a 255 ± 8b
Heart weight, mg 1312 ± 43 1127 ± 35a 1400 ± 49b
(Heart weight)/(body weight), mg/g 3.83 ± 0.04 5.72 ± 0.19a 5.25 ± 0.12a
Balloon volume to increase EDP
from 0 to 10 mmHg, ll
75.65 ± 6.45 81.29 ± 7.63 56.38 ± 5.69b
RV/LV + septum weight ratio 0.33 ± 0.02 0.59 ± 0.03a 0.59 ± 0.02a
MDA, mM 0.175 ± 0.018 0.215 ± 0.015a 0.213 ± 0.02a
NOx, lM 2.58 ± 0.86 8.82 ± 1.50
a 12.59 ± 0.73ab
Data are mean values ± SEM
aP < 0.05 versus N
bP < 0.05 versus CH
RBC, red blood cell counts; MDA, plasma malondialdehyde; NOx, nitrates/nitrites index
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Fig. 2 Left Panels: Phosphorylated MAPK protein levels for JNK (A), ERK1/2 (C),
and p38-MAPK (E) in cytosolic and nuclear fractions in rats exposed to AH (1 h;
white), SAH (grey), CH (black), and CHA (hatched bars). Upper bands show total
MAPK proteins, lower bands show corresponding phosphorylated MAPK
proteins. Right panels: Specific in vitro kinase activities for JNK (B), ERK1/2 (D),
and p38-MAPK (F). Data are fold-increases (mean ± SD) over normoxic levels.
*P < 0.05 versus N; **P < 0.01 versus N; #P < 0.05 versus CH; ##P < 0.01
versus CH (n = 6/group)
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LV function per se in normoxic rats. PD98059 did
not abolish the improvement in LVDP · HR in
CHA compared with CH (Fig. 5D, E). Posthypoxic
LVEDP was augmented in CH but normal in CHA
(Fig. 6A, E). Both SB203580 and SB202190 reduced
posthypoxic LVEDP in CH, but not in normoxic
controls (Fig. 6B, C). PD98059 increased LVEDP in
CHA (Fig. 6D, E); however, vehicle alone caused
comparable changes (data not shown) consistent
with nonspecific effects.
Discussion
The major findings in the present study are as follows:
(1) MAPK signaling cascades are differentially acti-
vated in acute and chronic myocardial hypoxia in
adult rats; (2) Chronic hypoxia is associated with in-
creased p38-MAPK activation, increased apoptosis,
and impaired recovery of LV function upon sudden
reoxygenation; (3) Repeated brief normoxic episodes
(1 h/day) during chronic hypoxia abolish p38-MAPK
activation, stimulate MEK-ERK1/2 activation mod-
estly, and fully restore posthypoxic recovery of LV
function; and (4) Pharmacological p38-MAPK block-
ade similarly restores posthypoxic LV function.
Acute and chronic hypoxia stimulated activation
of different MAPK signaling cascades in adult rat
myocardium. While acute hypoxia was associated
with increased activation of both JNK and p38-
MAPK, chronic hypoxia enhanced p38-MAPK sig-
naling alone. Thus, sustained hypoxia appears to
maintain p38-MAPK in a chronically activated state,
which potentially stimulates target nuclear factors
and gene expression. This is exemplified by a 60%
increase in the expression of c-fos, a p38-MAPK
target gene, in chronic hypoxia (data not shown).
Our results are concordant with recent data show-
ing increased activation of both JNK and p38-
MAPK in cardiac tissues from chronically hypoxic
infant rabbits and humans [23], except that JNK
activation was not increased in chronically hypoxic
rats in the present study. Methodological factors
that could account for differences in JNK activation
between the two studies include species, age, and
type of hypoxic chambers used. Previous protocols
used conventional hypoxic chambers that required a
20–30 min normoxic period daily [2, 13, 23]. In the
rabbit model mentioned above [23], infant rabbits
were housed in hypoxic chambers but returned to
their mothers for a 30 min feeding period daily,
during which they were allowed to breathe room air
[2, 23]. In contrast, we have designed novel hypoxic
chambers that avoid any exposure to room air
throughout chronic hypoxia (including sacrifice and
heart recovery).
Chronic hypoxia was associated with detrimental
effects, such as impaired posthypoxic recovery of LV
function and increased apoptosis. Previous studies
have suggested that the myocardium may adapt to
chronic hypoxia and become more tolerant to
ischemia-reperfusion injury [2, 7, 18, 23]. In a rat
model, however, adaptation was confined to the right
ventricle [7]. The present study focused on hypoxia-
reoxygenation, rather than ischemia-reperfusion, in-
jury, which prevents a direct comparison of our re-
sults with those obtained in ischemic models. In the
clinical setting, hypoxia-reoxygenation injury occurs
at institution of cardiopulmonary bypass in cyanotic
infants during surgical repair of their heart defects.
Experimental studies of hypoxia-reoxygenation
injury without aortic clamping showed a higher
magnitude of damage compared with ischemia-rep-
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Data are mean values ± SEM (n = 7–11/group)
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Fig. 6 Posthypoxic recovery of diastolic LV function and MAPK inhibitors. (A)
LV end-diastolic pressure (LVEDP) during initial equilibration (starting at time 0
and ending at 30 min) and subsequent reoxygenation (starting at 30 min and
ending at 60 min). LVEDP at the end of reoxygenation was increased in CH but
normal in CHA. (B, C) Effects of p38-MAPK inhibition by SB203580 and
SB202190, respectively, in CH and N. Both p38-MAPK inhibitors normalized
LVEDP in CH but did not reduce it in N hearts. (D) Effect of MEK1-ERK1/2
inhibition in CHA. PD98059 increased LVEDP in CHA (similar changes were
observed with vehicle alone; data not shown). (E) Summary graph of the effects
of SB203580 (grey bars), SB202190 (black bars), and PD98059 (hatched bars),
as compared with no treatment (white bars), on LVEDP in N, CH, and CHA
(n = 7–11/group). Data are mean values ± SEM
S. Morel et al. 343
MAPKs in chronic hypoxia
erfusion injury [11]. Our results are in good agree-
ment with a few studies in large animal models in
which chronic hypoxia was induced by using surgi-
cal techniques [9, 16, 25]. In addition, they are
consistent with clinical evidence suggesting that
cyanotic infants and children have a higher inci-
dence of prolonged and complicated courses after
successful heart surgery compared with noncyanotic
ones [12, 17, 21, 22]. Again, it is conceivable that
some protective effects attributed to chronic hypoxia
in models that utilized conventional hypoxic cham-
bers were actually due to intermittent normoxic
episodes during daily opening of the cages.
In the present study, exposure of chronically
hypoxic rats to room air for a 1 h period daily abol-
ished p38-MAPK, while enhancing MEK1-ERK1/2
activation modestly. In comparison, a 1 h exposure to
room air following 2 weeks of hypoxia reduced
phosphorylated p38-MAPK protein levels by just
30%. Intermittent reoxygenation for 1 h/day was
paralleled by decreased apoptosis and restored post-
hypoxic recovery of LV function in chronically hyp-
oxic hearts. Although cardioprotection mediated by
intermittent hypoxia (4–6 h/day) was reported re-
cently [28], it is worth noting that our results refer to
intermittent reoxygenation (1 h/day) during chronic
hypoxia, rather than intermittent hypoxia. The
mechanism underlying the protective effect is
incompletely understood. Bursts of reactive oxygen
species generated during normoxic exposure after
prolonged hypoxia add to oxidative stress, as evi-
denced by increased NOx in the present study. It has
been shown that oxidative stress induced by precon-
ditioning contributes to the second window of pro-
tection by endogenous antioxidant enzymes in
myocytes [27].
The role of p38-MAPK in hypoxia-reoxygenation
injury is still controversial. p38-MAPK has been
implicated in ischemic preconditioning in a pig
model [24]. A number of factors, such as species,
age, preconditioning, hypoxia-reoxygenation or
ischemia-reperfusion injury, and timing of drug
administration have been shown to influence the
outcome of p38-MAPK inhibition [24]. In the pres-
ent study, two different p38-MAPK inhibitors,
SB203580 and SB202190, abolished p38-MAPK acti-
vation and restored posthypoxic recovery of LV
function in chronically hypoxic rats, in the absence
of nonspecific effects in normoxic hearts. These
findings support a central role for p38-MAPK as a
negative regulator of myocardial function in chronic
hypoxia. They are consistent with recent data
showing that p38-MAPK mediates a negative ino-
tropic effect in cardiomyocytes [14].
At least four members of the p38-MAPK family
have been identified, and its variable effects may be
accounted for by the relative expression of a partic-
ular isoform. The isoforms a and b are both expressed
in the heart and may have opposing effects. Ischemia
activates the p38a but not p38b isoform in myocytes,
a potentially detrimental pattern. The two p38-MAPK
inhibitors used in the present study inhibit both p38a
(SAPKa) and p38b (SAPKb2) [4]. The distinct roles of
p38a and p38b in myocardial impairment in chronic
hypoxia remain to be determined.
In the present study, we mainly focused on p38-
MAPK activation as the most pronounced effect of
chronic hypoxia on the three major MAPK families.
Pharmacological p38-MAPK inhibition was sufficient
to fully reverse the detrimental effect of chronic hy-
poxia on posthypoxic LV function. Thus, p38-MAPK
inhibition induced by brief normoxic episodes during
chronic hypoxia would be sufficient to explain the
protective effect observed. Contributory roles for
ERK1/2 [15] and JNK activation to this effect are
possible, but have not been extensively characterized
in the present study. Intermittent reoxygenation
activated the MEK1-ERK1/2 signaling pathway only
modestly, and the protective effect was not abrogated
by PD98059, a specific MEK1 inhibitor. Moreover,
intermittent reoxygenation induced in vitro JNK
activity only modestly in nuclear fractions, and this
was not accompanied by a parallel increase in phos-
phorylated JNK protein levels. Further investigations
are needed to more precisely characterize the bio-
logical relevance of the modest changes in ERK1/2
and JNK activation induced by intermittent reoxy-
genation in the present study.
Experimental evidence for hypoxic adaptation does
not appear to translate into any clinically relevant
cardiac protection in children undergoing surgical
repair of a cyanotic heart defect. Our data suggest that
preoperative intermittent reoxygenation and phar-
macological p38-MAPK inhibition might be benefi-
cial. Parenthetically, it has been shown that breathing
hyperoxic gas ([FIO2] = 0.80) for 1 h induces both
immediate and delayed cardioprotection in rats [26].
Regarding pharmacological approaches, a specific
p38-MAPK inhibitor is being tested in initial clinical
trials in rheumatoid arthritis [10]. Further studies are
needed to evaluate the usefulness of these approaches
in preclinical models of chronic hypoxia.
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